Spotlight -

PBMI Innovators|

2026 State of Pharmacy survey results available now|

Our July 2026 issue

Opinion|Videos|December 17, 2024

PPF Symptoms and Impact on Quality of Life

Author(s)Anna-Maria Hoffmann-Vold, M.D., Ph.D.

Anna-Maria Hoffmann-Vold, M.D., Ph.D., discusses the most common symptoms of progressive pulmonary fibrosis (PPF), how they typically evolve and the impact of PPF on patients’ daily activities and quality of life as the disease progresses.

Episodes in this series

EP. 1 Understanding PPF and Its Risk Factors

EP. 1 Understanding PPF and Its Risk Factors

EP. 2 PPF Symptoms and Impact on Quality of Life

EP. 2 PPF Symptoms and Impact on Quality of Life

EP. 3 Diagnosing PPF and the Importance of Early Detection

EP. 3 Diagnosing PPF and the Importance of Early Detection

EP. 4 Current Treatment Approaches for PPF: Pharmacological and Nonpharmacological

EP. 4 Current Treatment Approaches for PPF: Pharmacological and Nonpharmacological

EP. 5 Key Unmet Needs in PPF Management

EP. 5 Key Unmet Needs in PPF Management

EP. 6 Emerging Therapies for PPF

EP. 6 Emerging Therapies for PPF

EP. 7 Potential Impact of Emerging PPF Treatments on Patient Outcomes and Health Ccare Resource Utilization

EP. 7 Potential Impact of Emerging PPF Treatments on Patient Outcomes and Health Ccare Resource Utilization

EP. 8 Enhancing Patient Care in Progressive Pulmonary Fibrosis: Strategies for Addressing Unmet Needs and Optimizing Treatment Approaches

EP. 8 Enhancing Patient Care in Progressive Pulmonary Fibrosis: Strategies for Addressing Unmet Needs and Optimizing Treatment Approaches

Video content above is prompted by the following:

What are the most common symptoms of progressive pulmonary fibrosis (PPF), and how do they typically evolve?
How does PPF impact patients’ activities of daily living and quality of life, and how do these challenges change as the disease progresses?

Newsletter

Get the latest industry news, event updates and more from Managed Healthcare Executive.

Related Content

Latest CME

Show Me Your Care Plan!™ Navigating ADC Therapies: Oncology Nursing Strategies for Optimal Patient Management

Show Me Your Care Plan!™ Navigating ADC Therapies: Oncology Nursing Strategies for Optimal Patient Management

August 24, 2026

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhD

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhD

Medical Crossfire®: ADCs and Bispecifics in Lung Cancer – Hype, Hope, or a New Standard of Care?

In-Person + Virtual Event

Medical Crossfire®: ADCs and Bispecifics in Lung Cancer – Hype, Hope, or a New Standard of Care?

September 12, 2026

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Jonathan Goldman, MD; Erminia Massarelli, MD, PhD, MS; Jorge J. Nieva, MD; Ignacio I. Wistuba, MD

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

Jonathan Goldman, MD; Sanja Dacic, MD, PhD; Deborah Doroshow, MD, PhD; Anne S. Tsao, MD, MBA

27th Annual International Lung Cancer Congress®

27th Annual International Lung Cancer Congress®

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FASCO

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Sandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHS

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Tina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhD

26th Annual International Lung Cancer Congress

26th Annual International Lung Cancer Congress

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FASCO

Tennessee Oncology Practice Society

Tennessee Oncology Practice Society

2 Sessions are Available!

20th Annual New York Lung Cancers Symposium®

20th Annual New York Lung Cancers Symposium®

Balazs Halmos, MD, MS; Jamie Chaft, MD

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Charles M. Rudin, MD, PhD; Anne Chiang, MD, PhD, FASCO; Jacob M. Sands, MD

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Shubham Pant, MD, MBBS; Alison Schram, MD; Helena Yu, MD

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

Millie Das, MD; Wade Iams, MD, MSCI; Ruham Nasany, MD

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

Trending on Managed Healthcare Executive

Researchers discover new pathway to fight liver inflammation

FDA approves $2.7 million gene therapy for rare metabolic disorder

Overlooked bladder nerves now thought to reduce UTI burden through pain signaling, study shows

HIV medication adherence follows SNAP payment timing, study finds

FDA approves Pasatru, the second treatment for rare bone disorder